Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876675 | 0.88 | CTSB (0.47) | CTSBCTSSCTSKAAK1SLC7A5 | |
| SCHEMBL14431669 | 0.88 | CTSB (0.47) | CTSBCTSSCTSKAAK1SLC7A5 | |
| SCHEMBL2476924 | 0.86 | MMP13 (0.46) | CTSBCTSSCTSKSLC7A5MMP13 | |
| SCHEMBL1401042 | 0.86 | MMP13 (0.46) | CTSBCTSSCTSKSLC7A5MMP13 | |
| SCHEMBL65502 | 0.86 | MMP13 (0.46) | CTSBCTSSCTSKSLC7A5MMP13 | |
| SCHEMBL15083607 | 0.85 | CTSL (0.49) | SLC7A5RIPK1MMP13 | |
| SCHEMBL31407294 | 0.85 | CTSB (0.50) | CTSBCTSSCTSKSLC7A5MMP13 | |
| SCHEMBL25185803 | 0.85 | CTSS (0.49) | CTSSCTSKSLC7A5RIPK1MMP13 | |
| SCHEMBL29540073 | 0.85 | CTSL (0.49) | SLC7A5RIPK1MMP13 | |
| SCHEMBL25182915 | 0.85 | SLC7A5 (0.44) | CTSBCTSSCTSKAAK1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CTSB 2004/4885CTSS 2182/4885CTSK 1790/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CTSB 2004/4885CTSS 2182/4885CTSK 1790/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CTSB 2004/4885CTSS 2182/4885CTSK 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.